Pharmacological Activation of Pyruvate Kinase M2 Inhibits CD4+-T Cell 
Pathogenicity and Suppresses Autoimmunity

Angiari, Stefano; Runtsch, Marah C.; Sutton, Caroline E.; Palsson-McDermott, Eva M.; Kelly, Beth; Rana, Nisha; Kane, Harry; Papadopoulou, Gina; Pearce, Erika L.; Mills, Kingston H.G.; O'Neill, Luke A.J.

doi:org/10.1016/j.cmet.2019.10.015

Datensatz

DATENSATZ AKTIONENEXPORT

Zur Ablage hinzufügen

Lokale TagsFreigabegeschichteDetailsÜbersicht

Freigegeben

Zeitschriftenartikel

Pharmacological Activation of Pyruvate Kinase M2 Inhibits CD4⁺-T Cell Pathogenicity and Suppresses Autoimmunity

MPG-Autoren

/persons/resource/persons201431

Pearce, Erika L.
Department Immunometabolism, Max Planck Institute of Immunobiology and Epigenetics, Max Planck Society;

Externe Ressourcen

https://www.sciencedirect.com/science/article/pii/S1550413119306060?via%3Dihub
(Verlagsversion)

Volltexte (beschränkter Zugriff)

Für Ihren IP-Bereich sind aktuell keine Volltexte freigegeben.

Volltexte (frei zugänglich)

Es sind keine frei zugänglichen Volltexte in PuRe verfügbar

Ergänzendes Material (frei zugänglich)

Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar

Zitation

Angiari, S., Runtsch, M. C., Sutton, C. E., Palsson-McDermott, E. M., Kelly, B., Rana, N., et al. (2020). Pharmacological Activation of Pyruvate Kinase M2 Inhibits CD4⁺-T Cell Pathogenicity and Suppresses Autoimmunity. Cell Metabolism, 31, 391-405. doi:org/10.1016/j.cmet.2019.10.015.

Zitierlink: https://hdl.handle.net/21.11116/0000-0006-3C98-C

Zusammenfassung

Pyruvate kinase (PK) catalyzes the conversion of phosphoenolpyruvate to pyruvate during glycolysis. The PK isoform PKM2 has additional roles in regulation of gene transcription and protein phosphorylation. PKM2 has been shown to control macrophage metabolic remodeling in inflammation, but its role in T cell biology is poorly understood. Here, we report PKM2 upregulation, phosphorylation, and nuclear accumulation in murine and human CD4+ T cells following activation in vitro. Treatment of T cells with TEPP-46, an allosteric activator that induces PKM2 tetramerization and blocks its nuclear translocation, strongly reduces their activation, proliferation, and cytokine production by inhibiting essential signaling pathways and thus preventing the engagement of glycolysis. TEPP-46 limits the development of both T helper 17 (Th17) and Th1 cells in vitro and ameliorates experimental autoimmune encephalomyelitis (EAE) in vivo. Overall, our results suggest that pharmacological targeting of PKM2 may represent a valuable therapeutic approach in T cell-mediated inflammation and autoimmunity.